Earnings History Data for Adaptimmune Therapeutics plc (ADAP) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Adaptimmune Therapeutics plc

Adaptimmune Therapeutics plc is a biopharmaceutical company. The Company is focused on cancer immunotherapy products based on T-cell receptor platform. Adaptimmune Therapeutics plc is based in Abingdon, United Kingdom.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
13-11-2024	AH		ADAP	Adaptimmune Therapeutics plc	210.76	-0.07	-0.17	-0.20	Adaptimmune GAAP EPS of -$0.01 beats by $0.07, revenue of $40.9M beats by $20.41M [11/13/2024 6:14 PM]	0.5937	-0.18 (-22.96%)	0.82	0.05 (6.41%)	0.42 - 2.05	14,194,438	900,000	17,725
Adaptimmune reports positive data in mid-stage trial of its sarcoma treatment [11/13/2024 9:27 AM] Adaptimmune to engage in restructuring; 33% headcount reduction [11/13/2024 4:46 PM] Adaptimmune GAAP EPS of -$0.01 beats by $0.07, revenue of $40.9M beats by $20.41M [11/13/2024 6:14 PM] Adaptimmune's Lete-cel Achieves Primary Endpoint in Pivotal Trial [2024-11-13 09:00AM] Adaptimmune Reports Q3 2024 Financial and Business Updates [2024-11-13 04:05PM] Adaptimmune Therapeutics PLC (ADAP) Q3 2024 Earnings Call Highlights: Strategic Restructuring ... [2024-11-14 02:15AM] Adaptimmune nears second sarcoma approval as Phase II trial hits endpoints [2024-11-14 11:55AM]
12-08-2024	PM		ADAP	Adaptimmune Therapeutics plc	252.24	0.27	0.00	-0.21	Adaptimmune GAAP EPS of $0.05 beats by $0.05, revenue of $128.2M beats by $83.44M [8/12/2024 7:09 AM]	1.08	0.09 (8.95%)	1.10	0.11 (10.79%)	0.42 - 2.05	3,868,265	3,510,000	434,284
Earnings summary: Adaptimmune Therapeutics beats Q2 estimates [8/12/2024 7:30 AM] Adaptimmune GAAP EPS of $0.04 beats by $0.04, revenue of $128.2M beats by $83.44M [8/12/2024 7:09 AM]
15-05-2024	PM		ADAP	Adaptimmune Therapeutics plc	276.44	-0.18	-0.16	0.01	Adaptimmune GAAP EPS of -$0.03 beats by $0.04, revenue of $5.7M misses by $11.37M [5/15/2024 7:45 AM]	1.21	0.06 (5.22%)	1.18	0.03 (2.61%)	0.42 - 2.05	1,318,569	780,000	67,402
Adaptimmune GAAP EPS of -$0.03 beats by $0.04, revenue of $5.7M misses by $11.37M [5/15/2024 7:45 AM] Adaptimmune Therapeutics gets $125M in financing from Hercules Capital [5/15/2024 7:36 AM] Adaptimmune Q1 2024 Earnings Preview [5/14/2024 1:24 PM]
06-03-2024	PM		ADAP	Adaptimmune Therapeutics	1,471	-0.24	-0.12	0.00		1.72	0.26 (17.81%)	1.55	0.09 (6.16%)	0.42 - 1.79	2,059,832	1,560,000	116,068
Adaptimmune Q4 2023 Earnings Preview [3/5/2024 11:53 AM]
08-11-2023	PM		ADAP	Adaptimmune Therapeutics plc	132.81	-0.20	-0.20	-0.24	Adaptimmune GAAP EPS of -$0.03 beats by $0.16, revenue of $7.3M misses by $7.84M [11/8/2023 7:37 AM]	0.5682	-0.03 (-4.66%)	0.57	-0.03 (-4.33%)	0.52 - 2.65	205,371	300,000	31,792
Adaptimmune Q3 2023 Earnings Preview [11/7/2023 11:53 AM] Adaptimmune GAAP EPS of -$0.03 beats by $0.16, revenue of $7.3M misses by $7.84M [11/8/2023 7:37 AM]
09-08-2023	PM		ADAP	Adaptimmune Therapeutics plc	142.50	-0.21	-0.17	-0.28	Adaptimmune GAAP EPS of -$0.02 beats by $0.19, revenue of $5.13M misses by $1.54M [8/9/2023 7:56 AM]	0.85	-0.01 (-1.16%)	0.0	0.0 (0.00%)	0.84 - 2.65	476,904	490,000	0
Adaptimmune Q2 2023 Earnings Preview [8/8/2023 2:26 PM] Adaptimmune GAAP EPS of -$0.02 beats by $0.19, revenue of $5.13M misses by $1.54M [8/9/2023 7:56 AM]
12-05-2023	PM	0:00 AM ET (May 12)	ADAP	Adaptimmune Therapeutics	217.00	0.01	-0.19	0.00	Adaptimmune GAAP EPS of $0.00 beats by $0.14, revenue of $47.6M [5/12/2023 8:39 AM]	1.37	0.01 (0.74%)	1.42	0.06 (4.41%)	1.01 - 2.65	396,651	590,000	3,845
Adaptimmune Q1 2023 Earnings Preview [5/11/2023 12:11 PM] Adaptimmune GAAP EPS of $0.00 beats by $0.14, revenue of $47.6M [5/12/2023 8:39 AM]
06-03-2023	PM	0:00 AM ET (Mar 6)	ADAP	Adaptimmune Therapeutics plc	265.40	-0.18	-0.25	-0.25	Adaptimmune GAAP EPS of -$0.03 beats by $0.20, revenue of $11.03M beats by $5.95M [3/6/2023 6:44 AM]	1.33	-0.43 (-24.43%)	1.38	-0.38 (-21.59%)	1.01 - 2.65	4,315,111	180,000	435,241
TCR² Therapeutics stock rise 41% after merger deal with Adaptimmune [3/6/2023 6:27 AM] Adaptimmune GAAP EPS of -$0.03 beats by $0.20, revenue of $11.03M beats by $5.95M [3/6/2023 6:44 AM] Adaptimmune sheds nearly 26% after strategic combination with TCR² Therapeutics; tops Q4 consensus [3/6/2023 7:27 AM]
08-11-2022	PM		ADAP	Adaptimmune Therapeutics plc	259.76	-0.24	-0.28	-0.27	Adaptimmune GAAP EPS of -$0.04 beats by $0.22, revenue of $7M beats by $2.03M [11/8/2022 8:33 AM]	2.09	0.43 (25.90%)	1.80	0.14 (8.43%)	1.01 - 5.95	1,409,268	360,000	11,223
Adaptimmune Q3 2022 Earnings Preview [11/7/2022 12:55 PM] Adaptimmune stock rises as drug shows promise across cancer types in phase 1 trial [11/8/2022 7:49 AM] Adaptimmune GAAP EPS of -$0.04 beats by $0.22, revenue of $7M beats by $2.03M [11/8/2022 8:33 AM] Adaptimmune Reports Third-Quarter Financial Results and Business Update [Nov-08-22 07:30AM] Adaptimmune Reports Increased Response Rate and Durability of Response in Its Phase 1 SURPASS trial; ORR Now 52% Across Ovarian, Urothelial, and Head & Neck Cancers [Nov-08-22 07:00AM]
04-08-2022	PM	7:30 AM ET (Aug 4)	ADAP	Adaptimmune Therapeutics plc	294.87	-0.28	-0.28	-0.24	Adaptimmune Non-GAAP EPS of -$0.05 beats by $0.24, revenue of $5.54M misses by $3.16M [8/4/2022 7:35 AM]	2.31	0.37 (19.07%)	3.92	-0.40 (-9.26%)	1.26 - 6.86	496,636	180,000	51,552
Gene editing companies benefitting from Roche deal with CAR-T player Poseida Therapeutics [8/3/2022 2:58 PM] Adaptimmune Q2 2022 Earnings Preview [8/3/2022 12:05 PM] Adaptimmune Non-GAAP EPS of -$0.05 beats by $0.24, revenue of $5.54M misses by $3.16M [8/4/2022 7:35 AM]
09-05-2022	PM	8:00 AM ET (May 9)	ADAP	Adaptimmune Therapeutics plc	279.22	-0.32	-0.26	-0.24	Adaptimmune GAAP EPS of -$0.05 beats by $0.19, revenue of $3.6M misses by $1.4M [5/9/2022 7:32 AM]	1.55	-0.16 (-9.36%)	1.71	0.0 (0.00%)	1.50 - 6.86	787,004	910,000	407
Adaptimmune GAAP EPS of -$0.05 beats by $0.19, revenue of $3.6M misses by $1.4M [5/9/2022 7:32 AM] Adaptimmune Reports First Quarter Financial Results and Business Update [May-09-22 07:30AM]
14-03-2022	PM	7:30 AM ET (Mar 14)	ADAP	Adaptimmune Therapeutics plc	295.23	-0.25	-0.22	-0.24	Adaptimmune GAAP EPS of -$0.04, revenue of $1.4M [3/14/2022 8:05 AM]	1.82	0.0 (0.00%)	1.85	0.03 (1.65%)	1.77 - 6.86	1,034,086	1,000,535	4,760
Adaptimmune GAAP EPS of -$0.04, revenue of $1.4M [3/14/2022 8:05 AM] Adaptimmune Reports Fourth Quarter and Full Year 2021 Financial Results and Business Update [Mar-14-22 08:00AM] Tenet Healthcare (THC) Up 55% in a Year: Is More Upside Left? [Mar-14-22 11:31AM]
04-11-2021	PM	7:30 AM ET (Nov 4)	ADAP	Adaptimmune Therapeutics plc	841.32	-0.27	0.05	-0.23	Adaptimmune EPS beats by $0.21, beats on revenue [11/4/2021 7:34 AM]	5.25	-0.22 (-4.02%)	5.25	0.0 (0.00%)	3.37 - 7.34	420,698	470,000	206
Adaptimmune Q3 2021 Earnings Preview [11/3/2021 1:40 PM] Adaptimmune EPS beats by $0.21, beats on revenue [11/4/2021 7:34 AM] Adaptimmune Reports Third Quarter Financial Results and Business Update [Nov-04-21 07:30AM] Adaptimmune Therapeutics plc (ADAP) Q3 2021 Earnings Call Transcript [Nov-04-21 04:00PM]
09-08-2021	AH	After the close (Aug 9)	ADAP	Adaptimmune Therapeutics plc	548.91	-0.24	-0.25	-0.24	Adaptimmune EPS beats by $0.20, beats on revenue [8/9/2021 4:05 PM]	3.57	0.12 (3.33%)	3.65	0.20 (5.80%)	3.37 - 10.93	1,327,051	420,000	32,419
Adaptimmune EPS beats by $0.20, beats on revenue [8/9/2021 4:05 PM] Adaptimmune sees cash on hand to fund operations into early 2023, shares rise 9% [8/10/2021 10:23 AM] Adaptimmune Reports Second Quarter Financial Results and Business Update [Aug-09-21 04:00PM] Adaptimmune Therapeutics plc (ADAP) Q2 2021 Earnings Call Transcript [Aug-09-21 06:30PM]
06-05-2021	PM	7:30 AM ET (May 6)	ADAP	Adaptimmune Therapeutics plc	831.82	-0.24	-0.25	-0.24	Adaptimmune EPS beats by $0.21, misses on revenue [5/6/2021 7:32 AM]	4.90	-0.22 (-4.30%)	4.90	0.0 (0.00%)	3.36 - 13.40	1,144,335	830,000	950
Adaptimmune EPS beats by $0.21, misses on revenue [5/6/2021 7:32 AM] Adaptimmune Reports First Quarter Financial Results and Business Update [May-06-21 07:30AM]
25-02-2021	PM	7:30 AM ET (Feb 25)	ADAP	Adaptimmune Therapeutics plc	920.93	-0.24	-0.23	-0.28	Adaptimmune EPS beats by $0.19, beats on revenue [2/25/2021 7:32 AM]	5.97	-0.02 (-0.33%)	6.02	0.03 (0.50%)	2.00 - 13.40	535,627	1,182,365	1,548
Adaptimmune EPS beats by $0.19, beats on revenue [2/25/2021 7:32 AM] Adaptimmune Reports Fourth Quarter / Full Year 2020 Financial Results and Business Update [Feb-25-21 07:30AM] Adaptimmune Therapeutics Plc to Host Earnings Call [Feb-25-21 06:15AM]
05-11-2020	PM	7:30 AM ET (Nov 5)	ADAP	Adaptimmune Therapeutics plc	808.62	-0.23	-0.23	-0.37	Adaptimmune EPS beats by $0.19, beats on revenue [11/5/2020 7:36 AM]	5.31	0.01 (0.19%)	5.31	0.0 (0.00%)	0.71 - 13.40	1,130,047	2,352,031	3,101

06-08-2020	PM	7:30 AM ET (Aug 6)	ADAP	Adaptimmune Therapeutics plc	1,390	-0.24	-0.24	-0.42	Adaptimmune EPS beats by $0.20, misses on revenue [8/6/2020 7:34 AM]	8.50	-0.22 (-2.52%)	8.70	-0.02 (-0.23%)	0.71 - 13.40	410,014	667,680	6,947

14-05-2020	PM	7:30 AM ET (May 14)	ADAP	Adaptimmune Therapeutics plc	641.39	-0.24	-0.13	-0.24	Adaptimmune EPS beats by $0.21, misses on revenue [5/14/2020 7:37 AM]	4.35	-0.19 (-4.18%)	4.65	0.11 (2.42%)	0.71 - 6.00	789,373	1,077,558	16,917